Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/60560
COMPARTIR / EXPORTAR:
logo share SHARE logo core CORE BASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE

Invitar a revisión por pares abierta
Título

Identification of potential biomarkers for giant cell tumor of bone using comparative proteomics analysis

AutorConti, Amalia; Caballero, Gemma; Dégano, Rosa M.; Barbado, Victoria; Álava, Enrique de CSIC ORCID
Fecha de publicación2011
EditorElsevier
CitaciónAmerican Journal of Pathology 178(1): 88-97 (2011)
ResumenGiant cell tumor of bone can be locally aggressive and occasionally can metastasize in the lungs. To identify new markers predictive of aggressive behavior, we analyzed five patients who developed lung metastasis and five who remained disease free for a minimum of 5 years. Using two-dimensional electrophoresis, we detected 28 differentially expressed spots. Fourteen spots were identified using mass spectrometry, including seven up-regulated and seven down-regulated in metastatic samples and classified according to functional categories. We then selected five proteins involved in cell cycle or apoptosis. Thioredoxin peroxidase, allograft inflammatory factor 1, and ubiquitin E2N had more than threefold up-regulation; glutathione peroxidase 1 had 1.9-fold up-regulation; and heat shock protein 27 showed down-regulation in metastatic samples with a very low P value. After validation and analysis of protein levels, evaluation of clinical impact was assessed in a much wider cohort of primary archival specimens. Immunodetection showed a higher frequency of thioredoxin peroxidase, allograft inflammatory factor 1, ubiquitin E2N, and glutathione peroxidase 1 overexpression in primary tumors that developed into lung metastases or that locally relapsed than in the disease-free group, with variable stain intensity and distribution. Kaplan-Meier analysis showed that high expression of glutathione peroxidase 1 was strongly related to local recurrence and metastasis, suggesting that its up-regulation may identify a subset of high-risk patients with giant cell tumor prone to receive diverse clinical management.
URIhttp://hdl.handle.net/10261/60560
DOI10.1016/j.ajpath.2010.11.035
Identificadoresdoi: 10.1016/j.ajpath.2010.11.035
issn: 0002-9440
e-issn: 1525-2191
Aparece en las colecciones: (IBMCC) Artículos




Ficheros en este ítem:
Fichero Descripción Tamaño Formato
accesoRestringido.pdf15,38 kBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro completo

CORE Recommender

PubMed Central
Citations

16
checked on 25-mar-2024

SCOPUSTM   
Citations

34
checked on 22-mar-2024

WEB OF SCIENCETM
Citations

33
checked on 25-feb-2024

Page view(s)

311
checked on 27-mar-2024

Download(s)

94
checked on 27-mar-2024

Google ScholarTM

Check

Altmetric

Altmetric


Artículos relacionados:


NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.